|drug1285||Duplex ultrasound and Computed Tomography Angiography Wiki||1.00|
|D016769||Embolism and Thrombosis NIH||0.50|
|D054556||Venous Thromboembolism NIH||0.35|
|D020246||Venous Thrombosis NIH||0.29|
There is one clinical trial.
During the new COVID-19 pandemic physicians all over the world have faced different challenges .Oxidative stress is a probable cause of multi organ failure in this setting which never has been evaluated in COVID-19 infection to the best of knowledge.Present study aimed to evaluate oxidative stress marker and redox system status in different COVID-19 patients regarding the severity of involvement.
Description: MDA x 2 ULN in severe COVIDMeasure: MDA concentration Time: 2 weeks
Description: Difference between severe and controlsMeasure: Biopterin concentration Time: 2 weeks
Description: Difference between severe and controlsMeasure: Neopterin rate of increase Time: 2 weeks
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports